Aurinia Pharmaceuticals — Q3 2026 Earnings Summary

Aurinia Pharmaceuticals reported total revenue of $83.7 million for the three months ended September 30, 2026, and $244.6 million for the nine-month period, representing increases of 14% and 19% respectively compared to the prior year. Net income for the nine months ended September 30, 2026, reached $103.5 million, driven primarily by net product sales of LUPKYNIS which totaled $232.4 million during the same period. The company increased its full-year 2026 total revenue guidance to a range of $325 million to $330 million and net product sales guidance to $310 million to $315 million. Additionally, Aurinia initiated the PRESERVE Phase 4 study to evaluate the combination of LUPKYNIS with other biologic agents for lupus nephritis and advanced clinical development of its dual inhibitor aritinercept.